Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up
AC

ACAD

Market Closed

ACADIA Pharmaceuticals Inc.

NASDAQHealthcareBiotechnology
US
798 employees
CEO: Catherine E. Owen Adams
Founded: 2004
$24.84
+$0.00(+NaN%)
Market Cap
4.25B
Beta
0.80
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: ACADIA trades 14.4% above its PERT-weighted fair value of $21.92, indicating potential overvaluation despite high confidence and strong financial health scores. Valuation metrics diverge sharply, with DCF showing negative value while P/E and analyst targets project substantial upside. Minimal downside in Monte Carlo scenarios indicates low price risk but growth score signals limited expansion prospects.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore ACAD

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

ACAD in the Healthcare

Mid Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms